{"product_id":"biostatistics-in-clinical-trials-isbn-9780471822110","title":"Biostatistics in Clinical Trials","description":"\u003cb\u003eThe second volume in the Wiley reference series in Biostatistics.\u003c\/b\u003e\u003cbr\u003eFeaturing articles from the prestigious Encyclopedia of Biostatistics, many of which have been fully revised and updated to include recent developments, Biostatistics in Clinical Trials also includes up to 25% newly commissioned material reflecting the latest thinking in: \u003cul\u003e \u003cli\u003eBayesian methods\u003c\/li\u003e \u003cli\u003eBenefit\/risk assessment\u003c\/li\u003e \u003cli\u003eCost-effectiveness\u003c\/li\u003e \u003cli\u003eEthics\u003c\/li\u003e \u003cli\u003eFraud\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eWith exceptional contributions from leading experts in academia, government and industry, Biostatistics in Clinical Trials has been designed to complement existing texts by providing extensive, up-to-date coverage and introducing the reader to the research literature.\u003cbr\u003eOffering comprehensive coverage of all aspects of clinical trials Biostatistics in Clinical Trials:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eIncludes concise definitions and introductions to numerous concepts found in current literature\u003c\/li\u003e \u003cli\u003eDiscusses the software and textbooks available\u003c\/li\u003e \u003cli\u003eUses extensive cross-references helping to facilitate further research and enabling the reader to locate definitions and related concepts\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eBiostatistics in Clinical Trials offers both academics and practitioners from various disciplines and settings, such as universities, the pharmaceutical industry and clinical research organisations, up-to-date information as well as references to assist professionals involved in the design and conduct of clinical trials.\u003c\/p\u003e\"Biostatistics in Clinical Trials\" gehört zur Reihe 'Wiley Reference Series in Biostatistics' und basiert auf der renommierten 'Encyclopedia of Biostatistics'. Dieser Band enthält 25% neues Material, umfassend aktualisierte Artikel und Verweise aus der Enzyklopädie sowie prägnante Definitionen und Einführungen in zahlreiche Grundlagen aus der aktuellen Literatur. Darüber hinaus wird eine Reihe neuer Themen behandelt, wie z.B. Bayesche Methoden, ethische Fragen und die Nutzen-Risiko-Bewertung. Durch umfangreiche Querverweise findet der Leser rasch Definitionen und verwandte Konzepte .  Adaptive and Dynamic Methods of Treatment Assignment.\u003cbr\u003e \u003cbr\u003e Antibacterial Agent Trials.\u003cbr\u003e \u003cbr\u003e Audit and Quality Control.\u003cbr\u003e \u003cbr\u003e Bayesian Methods.\u003cbr\u003e \u003cbr\u003e Benefit\/Risk Assessment.\u003cbr\u003e \u003cbr\u003e Binding or Masking.\u003cbr\u003e \u003cbr\u003e Clinical Significance Versus Statistical Significance.\u003cbr\u003e \u003cbr\u003e Clinical Trials, Overview.\u003cbr\u003e \u003cbr\u003e Cluster Randomization.\u003cbr\u003e \u003cbr\u003e Cochrane Collaboration.\u003cbr\u003e \u003cbr\u003e Community Intervention Trials.\u003cbr\u003e \u003cbr\u003e Compliance Assessment.\u003cbr\u003e \u003cbr\u003e CONSORT.\u003cbr\u003e \u003cbr\u003e Controlled Clinical Trials.\u003cbr\u003e \u003cbr\u003e Cooperative Cancer Trials.\u003cbr\u003e \u003cbr\u003e Cooperative Heart Disease Trials.\u003cbr\u003e \u003cbr\u003e Cooperative Studies Program, US Department of Veterans Affairs.\u003cbr\u003e \u003cbr\u003e Cost-effectiveness.\u003cbr\u003e \u003cbr\u003e Covariate Imbalance, Adjustment for.\u003cbr\u003e \u003cbr\u003e Crossover Designs.\u003cbr\u003e \u003cbr\u003e Data and Safety Monitoring.\u003cbr\u003e \u003cbr\u003e Data and Safety Monitoring Boards.\u003cbr\u003e \u003cbr\u003e Data Management and Coordination.\u003cbr\u003e \u003cbr\u003e Drug Approval and Regulation.\u003cbr\u003e \u003cbr\u003e Drug Interactions.\u003cbr\u003e \u003cbr\u003e Eligibility and Exclusion Criteria.\u003cbr\u003e \u003cbr\u003e Equivalence Trials.\u003cbr\u003e \u003cbr\u003e Ethics.\u003cbr\u003e \u003cbr\u003e European Federation of Statisticians in the Pharmaceutical Industry (EFPSI).\u003cbr\u003e \u003cbr\u003e European Organization for Research and Treatment of Cancer (EORTC).\u003cbr\u003e \u003cbr\u003e Factorial Designs.\u003cbr\u003e \u003cbr\u003e Fraud.\u003cbr\u003e \u003cbr\u003e Group-randomization Designs.\u003cbr\u003e \u003cbr\u003e Guidelines.\u003cbr\u003e \u003cbr\u003e Historical Controls, Bias From.\u003cbr\u003e \u003cbr\u003e History, Early Cancer and Heart Disease Trials.\u003cbr\u003e \u003cbr\u003e History, Overview.\u003cbr\u003e \u003cbr\u003e Intention-to-Treat Analysis.\u003cbr\u003e \u003cbr\u003e International Studies of Infarct Survival (ISIS).\u003cbr\u003e \u003cbr\u003e Medical Ethics and Statistics.\u003cbr\u003e \u003cbr\u003e Medical Research Council (MRC) Streptomycin Trial.\u003cbr\u003e \u003cbr\u003e Meta-analysis.\u003cbr\u003e \u003cbr\u003e Missing Data.\u003cbr\u003e \u003cbr\u003e Multicenter Trials.\u003cbr\u003e \u003cbr\u003e Multiple Endpoints.\u003cbr\u003e \u003cbr\u003e Multiplicity.\u003cbr\u003e \u003cbr\u003e Noncompliance, Adjustment for.\u003cbr\u003e \u003cbr\u003e Nonrandomized Trials.\u003cbr\u003e \u003cbr\u003e NSABP and Advances in the Treatment of Breast Cancer.\u003cbr\u003e \u003cbr\u003e Number Needed to Treat (NNT).\u003cbr\u003e \u003cbr\u003e Outcome Measures.\u003cbr\u003e \u003cbr\u003e Pharmaceutical Industry, Statistics in.\u003cbr\u003e \u003cbr\u003e Phase I Trials.\u003cbr\u003e \u003cbr\u003e Phase II Trials.\u003cbr\u003e \u003cbr\u003e Physicians' Health Study.\u003cbr\u003e \u003cbr\u003e Postmarketing Surveillance of New Drugs and Assessment of Risk.\u003cbr\u003e \u003cbr\u003e Preclinical Treatment Evaluation.\u003cbr\u003e \u003cbr\u003e Prevention Trials.\u003cbr\u003e \u003cbr\u003e Protocols.\u003cbr\u003e \u003cbr\u003e QUOROM.\u003cbr\u003e \u003cbr\u003e Randomization.\u003cbr\u003e \u003cbr\u003e Randomized Treatment Assignment.\u003cbr\u003e \u003cbr\u003e Salk Vaccine.\u003cbr\u003e \u003cbr\u003e Sample Size Determination.\u003cbr\u003e \u003cbr\u003e Screening Trials.\u003cbr\u003e \u003cbr\u003e Sequential Methods.\u003cbr\u003e \u003cbr\u003e Society for Clinical Trials.\u003cbr\u003e \u003cbr\u003e Software.\u003cbr\u003e \u003cbr\u003e Statistical Review for Medical Journals.\u003cbr\u003e \u003cbr\u003e Statistical Review for Medical Journals, Guidelines for Authors.\u003cbr\u003e \u003cbr\u003e Statisticians in the Pharmaceutical Industry (PSI).\u003cbr\u003e \u003cbr\u003e Surrogate Endpoints.\u003cbr\u003e \u003cbr\u003e Textbooks.\u003cbr\u003e \u003cbr\u003e Time-varying Treatment Effect.\u003cbr\u003e \u003cbr\u003e Treatment--Covariate Interaction.\u003cbr\u003e \u003cbr\u003e University Group Diabetes Program (UGDP).\u003cbr\u003e \u003cbr\u003e Vaccine Studies.  \"Every professional statistician should have this well written and well composed book in his\/her collection.\" (\u003ci\u003eJournal of Statistical Computation and Simulation\u003c\/i\u003e, September 2005)  \u003cp\u003e\"...strongly recommended as a reference for an overview of biostatistics in clinical trials...\" (\u003ci\u003eStatistical Methods in Medical Research\u003c\/i\u003e, Vol.12, No.4, 2003)\u003c\/p\u003e \u003cp\u003e\"highly informative and useful book\" (\u003ci\u003eJournal of Tropical Paediatrics\u003c\/i\u003e, February 2002)\u003c\/p\u003e \u003cp\u003e\"This highly informative and readable book is part of the Wiley Reference Series in Biostatistics. This book will be a useful tool for generating the required evidence and is a handy reference for the design, conduct, analysis and interpretation of clinical trials.\" (\u003ci\u003eJournal of Tropical Pediatricstrics\u003c\/i\u003e)\u003c\/p\u003e \u003cp\u003e\"...a valuable reference and an excellent resource to add to classroom and other teaching tools...\" (\u003ci\u003eOncology\u003c\/i\u003e, Vol.63, No.1, 2002) \u003c\/p\u003e \u003cp\u003e\u003cb\u003eCAROL K. REDMOND\u003c\/b\u003e, University of Pittsburgh, Pittsburgh, Pennsylvania, USA\u003cbr\u003eCarol Redmond earned an M.S. and Sc.D. in Biostatistics from the University of Pittsburgh. She has been a faculty member at the University of Pittsburgh Graduate School of Public Health since 1967 and served as Professor and Chairperson of the Department of Biostatistics from 1983 through 1996. She is presently Distinguished Service Professor and Vice Dean for Academic Affairs at the Graduate School of Public Health. From 1978 to 1994 she was the Founding Director of the Biostatistical Center for the National Surgical Adjuvant Breast and Bowel Project (NSABP), a cooperative clinical trial group that has conducted landmark randomized multicenter clinical trials for treatment and prevention of breast cancer. She has authored or co-authored more than 160 articles in biostatistical or biomedical publications. She is a previous member of the Editorial Boards for Statistics in Medicine and the Journal of Clinical Oncology. Dr. Redmond has been the recipient of a number of awards and honors including election as a Fellow of the American Statistical Association and the American College of Epidemiology. She has served as elected chair of the Statistics Section of the American Public Health Association and is currently President-Elect of the Biometric Society (Eastern North American Region) and a member of the Executive Committee of the International Society for Clinical Biostatistics. She has also participated in numerous peer review groups, advisory panels, and data monitoring committees for government and private agencies, including several of the National Institutes of Health, the Department of Veterans Affairs, and the Centers for Disease Control.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eTHEODORE COLTON\u003c\/b\u003e, Boston University, Boston, Massachusetts, USA\u003cbr\u003eTheodore Colton earned an M.S. in Statistics from the University of North Carolina and an Sc.D. in Biostatistics from Johns Hopkins School of Hygiene and Public Health. He has held faculty positions at Harvard Medical School, Dartmouth Medical School, and Boston University School of Public Health where he is currently Professor and Chair of the Department of Epidemiology and Biostatistics. He was twice the recipient of fellowship awards, from the National Science Foundation and the National Institutes of Health, for study at the London School of Hygiene and Tropical Medicine. He was one of the founding editors in 1981 of the Wiley Journal Statistics in Medicine and has served as editor through 1997, nurturing the growth of the journal from 381 pages in four issues in 1982 to 2972 pages in twenty-four issues in 1997. He is author of the textbook, Statistics in Medicine. Dr. Colton has served as a member of the Editorial Board of the New England Journal of Medicine and has been a biostatistical consultant to the editors of the Journal of the American Medical Association. He is a fellow of the American Statistical Association, the American College of Epidemiology, and the American Association for the Advancement of Science and he has served as president of Biometrics (Eastern North-American Region) and the Statistics Section of the American Public Health Association. He has served and continues to serve on numerous advisory committees and peer review groups for governmental agencies including the National Institutes of Health, the Centers for Disease Control, and the Department of Veterans Affairs.\u003c\/p\u003e  The second volume in the Wiley reference series in Biostatistics.\u003cbr\u003e \u003cbr\u003e Featuring articles from the prestigious Encyclopedia of Biostatistics, many of which have been fully revised and updated to include recent developments, Biostatistics in Clinical Trials also includes up to 25% newly commissioned material reflecting the latest thinking in:\u003cbr\u003e * Bayesian methods\u003cbr\u003e \u003cbr\u003e * Benefit\/risk assessment\u003cbr\u003e \u003cbr\u003e * Cost-effectiveness\u003cbr\u003e \u003cbr\u003e * Ethics\u003cbr\u003e \u003cbr\u003e * Fraud\u003cbr\u003e With exceptional contributions from leading experts in academia, government and industry, Biostatistics in Clinical Trials has been designed to complement existing texts by providing extensive, up-to-date coverage and introducing the reader to the research literature.\u003cbr\u003e \u003cbr\u003e Offering comprehensive coverage of all aspects of clinical trials Biostatistics in Clinical Trials:\u003cbr\u003e * Includes concise definitions and introductions to numerous concepts found in current literature\u003cbr\u003e \u003cbr\u003e * Discusses the software and textbooks available\u003cbr\u003e \u003cbr\u003e * Uses extensive cross-references helping to facilitate further research and enabling the reader to locate definitions and related concepts\u003cbr\u003e Biostatistics in Clinical Trials offers both academics and practitioners from various disciplines and settings, such as universities, the pharmaceutical industry and clinical research organisations, up-to-date information as well as references to assist professionals involved in the design and conduct of clinical trials.","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47988842561765,"sku":"NP9780471822110","price":631.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780471822110.jpg?v=1761781739","url":"https:\/\/k12savings.com\/products\/biostatistics-in-clinical-trials-isbn-9780471822110","provider":"K12savings","version":"1.0","type":"link"}